Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vaccines and outlook for 2H19 at FNN's Investor Event.
Key points: - An emerging leader in cancer immuno-oncology
- Strong preliminary results from ongoing clinical trials
- Robust pipeline of B-cell vaccines targeting high potential areas
- Fully funded to progress clinical program
- Best in class leadership team with a track record in drug development
- Active market with numerous commercialisation opportunities in the sector
- Promising Phase 1 clinical trial results
For more, watch MD & CEO Leslie Chong present.
